Sage Mountain Advisors LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)

Sage Mountain Advisors LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 5.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,168 shares of the company’s stock after purchasing an additional 202 shares during the quarter. Sage Mountain Advisors LLC’s holdings in Novo Nordisk A/S were worth $431,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of NVO. Jennison Associates LLC lifted its position in shares of Novo Nordisk A/S by 100.3% during the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after acquiring an additional 11,727,507 shares in the last quarter. FMR LLC raised its stake in shares of Novo Nordisk A/S by 122.7% during the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares during the period. Morgan Stanley raised its stake in shares of Novo Nordisk A/S by 96.5% during the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after purchasing an additional 4,526,199 shares during the period. Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 91.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after purchasing an additional 4,350,862 shares during the period. Finally, Polen Capital Management LLC bought a new position in Novo Nordisk A/S in the 3rd quarter worth about $718,995,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.1 %

Shares of NVO stock opened at $125.23 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The company has a market capitalization of $561.97 billion, a PE ratio of 46.30, a price-to-earnings-growth ratio of 2.05 and a beta of 0.41. The business’s fifty day moving average is $126.49 and its 200 day moving average is $111.28.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NVO. BMO Capital Markets started coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.